⌕
Pharvaris · PHVS · Nasdaq
Tenet — · insufficient data
Compare
$31.66+0.35%At close
$31.66+0.11 (+0.35%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD
Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.

Pharvaris (PHVS) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Zacks Investment ResearchNov 16, 2026 · 10:55 ET
Wall Street Analysts See a 79.41% Upside in Pharvaris (PHVS): Can the Stock Really Move This High?

The mean of analysts' price targets for Pharvaris (PHVS) points to a 79.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnin…

● GlobeNewsWireNov 12, 2026 · 10:28 ETCOMPANY'S OWN WORDS
Pharvaris Presents Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting

ZUG, Switzerland, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living w…

● GlobeNewsWireNov 12, 2026 · 06:50 ETCOMPANY'S OWN WORDS
Pharvaris Reports Third Quarter 2026 Financial Results and Provides Business Update

ZUG, Switzerland, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living w…

● GlobeNewsWireOct 29, 2026 · 06:50 ETCOMPANY'S OWN WORDS
Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting

Pivotal, Phase 3 CHAPTER-3 data selected for late-breaking oral presentation on Saturday, November 14 Pivotal, Phase 3 CHAPTER-3 data selected for late-breaking oral presentation on Saturday, November 14…

● BenzingaOct 23, 2026 · 14:06 ET
Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade

Bank of America Securities on Friday upgraded Pharvaris N.V. (NASDAQ:PHVS), citing an attractive entry point with clinical risk largely removed.…

● GlobeNewsWireOct 8, 2026 · 18:35 ET
Phase 3 Study Results Highlighting Deucrictibant's Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet

ZUG, Switzerland, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bra…

● Defense WorldSep 22, 2026 · 04:53 ET
Pharvaris (NASDAQ:PHVS) Director Robert Glassman Sells 14,493 Shares of Stock

Pharvaris N.V. (NASDAQ: PHVS - Get Free Report) Director Robert Glassman sold 14,493 shares of Pharvaris stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $38.56, for a to…

● Defense WorldSep 22, 2026 · 04:53 ET
Pharvaris (NASDAQ:PHVS) Insider Anne Lesage Sells 20,000 Shares

Pharvaris N.V. (NASDAQ: PHVS - Get Free Report) insider Anne Lesage sold 20,000 shares of the company's stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $38.27, for a total …

● Defense WorldSep 16, 2026 · 05:10 ET
Anne Lesage Sells 30,000 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ: PHVS - Get Free Report) insider Anne Lesage sold 30,000 shares of the company's stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $38.30, for a total…

● Defense WorldSep 16, 2026 · 04:37 ET
Pharvaris N.V. $PHVS Position Trimmed by Squarepoint Ops LLC

Squarepoint Ops LLC lowered its stake in Pharvaris N.V. (NASDAQ: PHVS) by 53.7% during a recent quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 44,629 shares of the co…

● Seeking AlphaSep 15, 2026 · 17:41 ET
Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

● Zacks Investment ResearchSep 15, 2026 · 10:51 ET
PHVS Stock Rises 10% in a Month: What Is Driving the Rally?

Pharvaris gains as strong phase III data show deucrictibant XR reduces HAE attacks 83%, supporting plans for regulatory submissions in 2027.…

● Seeking AlphaSep 9, 2026 · 14:18 ET
Pharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial Win

Pharvaris N.V. maintains a 'Strong Buy' rating following pivotal phase 3 wins for both on-demand and prophylactic HAE therapies. PHVS achieved rapid symptom relief in RAPIDe-3 [median 1.28 hours, p…

● Seeking AlphaSep 8, 2026 · 13:45 ET
Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema Transcript

Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema Transcript…

● ReutersSep 8, 2026 · 07:52 ET
Pharvaris' genetic disorder drug meets main goal in late-stage trial

Pharvaris said on Tuesday its experimental oral drug helped prevent swelling attacks in patients with hereditary angioedema, meeting ​the main goal of a late-stage trial.…

● GlobeNewsWireSep 8, 2026 · 06:50 ETCOMPANY'S OWN WORDS
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks

ZUG, Switzerland, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living …

● GlobeNewsWireSep 3, 2026 · 06:50 ETCOMPANY'S OWN WORDS
Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026

ZUG, Switzerland, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with br…

● Defense WorldSep 3, 2026 · 03:50 ET
BlackRock Inc. Makes New Investment in Pharvaris N.V. $PHVS

BlackRock Inc. purchased a new stake in shares of Pharvaris N.V. (NASDAQ: PHVS) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 771,454 share…

● Defense WorldAug 26, 2026 · 04:13 ET
5AM Venture Management LLC Makes New $27.58 Billion Investment in Pharvaris N.V. $PHVS

5AM Venture Management LLC bought a new stake in shares of Pharvaris N.V. (NASDAQ: PHVS) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 797,600…

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

ANT24−6.6%
NVDA7−2.3%
FOX6−2.9%
AMD3−6.0%

Article counts from the last market-wide feed page, across every symbol we track and not just PHVS · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.